Omeros (NASDAQ:OMER) Earns Buy Rating from D. Boral Capital

Omeros (NASDAQ:OMER)‘s stock had its “buy” rating reaffirmed by research analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $36.00 price target on the biopharmaceutical company’s stock. D. Boral Capital’s target price indicates a potential upside of 281.76% from the company’s current price.

A number of other equities analysts have also recently commented on OMER. HC Wainwright lifted their target price on shares of Omeros from $9.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, October 15th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Wednesday, October 15th. WBB Securities reiterated a “strong-buy” rating and issued a $45.00 price objective on shares of Omeros in a report on Wednesday, October 15th. Wall Street Zen cut Omeros from a “hold” rating to a “sell” rating in a report on Saturday, November 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Omeros in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Omeros has an average rating of “Moderate Buy” and a consensus target price of $33.67.

Omeros Price Performance

NASDAQ:OMER opened at $9.43 on Monday. The company has a market capitalization of $668.59 million, a price-to-earnings ratio of -4.47 and a beta of 2.40. The business has a 50 day moving average of $6.98 and a 200 day moving average of $4.87. Omeros has a 1-year low of $2.95 and a 1-year high of $13.60.

Omeros (NASDAQ:OMER) last issued its quarterly earnings results on Thursday, November 13th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.39. As a group, sell-side analysts anticipate that Omeros will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Omeros

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in shares of Omeros by 1,201.1% during the third quarter. JPMorgan Chase & Co. now owns 416,153 shares of the biopharmaceutical company’s stock valued at $1,706,000 after buying an additional 384,168 shares during the period. Two Sigma Investments LP lifted its stake in Omeros by 39.3% in the third quarter. Two Sigma Investments LP now owns 933,314 shares of the biopharmaceutical company’s stock worth $3,827,000 after acquiring an additional 263,095 shares during the period. Wellington Management Group LLP bought a new stake in Omeros in the first quarter valued at $1,118,000. Millennium Management LLC increased its position in Omeros by 49.1% during the 3rd quarter. Millennium Management LLC now owns 401,814 shares of the biopharmaceutical company’s stock valued at $1,647,000 after purchasing an additional 132,393 shares during the period. Finally, Nuveen LLC purchased a new position in Omeros during the 1st quarter valued at $938,000. Hedge funds and other institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.